Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.
Authors
Soria, J-CMárk, Z
Zatloukal, P
Szima, B
Albert, I
Juhász, E
Pujol, J L
Kozielski, J
Baker, N
Smethurst, D
Hei, Y J
Ashkenazi, A
Stern, H
Amler, L
Pan, Y
Blackhall, Fiona H
Affiliation
South Paris University, Institut Gustave Roussy, Villejuif, France.Issue Date
2011-11-20
Metadata
Show full item recordAbstract
To evaluate the efficacy and safety of dulanermin combined with paclitaxel and carboplatin (PC) and bevacizumab (PCB) as first-line treatment for advanced or recurrent non-small-cell lung cancer (NSCLC).Citation
Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. 2011, 29 (33):4442-51 J Clin OncolJournal
Journal of Clinical OncologyDOI
10.1200/JCO.2011.37.2623PubMed ID
22010015Type
ArticleLanguage
enISSN
1527-7755ae974a485f413a2113503eed53cd6c53
10.1200/JCO.2011.37.2623